BPC-157 in tendon, ligament and musculoskeletal soft-tissue injury — evidence extract

§1Evidence extract: Tendon, ligament and musculoskeletal soft-tissue injury

§1.1Question and anchor outcome

Population

Acute or overuse injury of tendon, ligament or muscle, with healing assessed by imaging, function and return-to-activity endpoints.

Intervention

BPC-157, subcutaneous, intraperitoneal or oral in preclinical studies; subcutaneous or oral in research contexts

Comparator

As used in each contributing trial; reported per trial rather than pooled across comparator types

Anchor outcome

Time to return to activity

Additional outcomes the Institute extracts for this indication: Pain on loading; Tendon thickness and structure on ultrasound; Re-injury rate.

§1.2Contributing trials

No trial has been identified for BPC-157 in tendon, ligament and musculoskeletal soft-tissue injury. No certainty rating is issued where that is so, for the reason given at §1.3.

§1.3Why no certainty rating is issued

The Institute rates certainty in a body of evidence. Where no eligible study has been identified there is no such body, and the domain-by-domain assessment used elsewhere in this series is not rendered: an inconsistency judgement requires two estimates to be inconsistent with one another, and an imprecision judgement requires an interval. Neither exists here.

The outcome is therefore recorded as not assessed. It is listed in the certainty index under that heading rather than at the lowest rating, because a rating of very low certainty says that evidence was found and is weak, and that is not what has happened.

What would change this: a controlled study in the population stated at §1.1, reporting the anchor outcome, retrievable in a form the Institute can appraise. The evidence gaps recorded in the monograph at §9 state what such a study would need to measure.

§1.4What this extract does not establish

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Prkacin I. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612–1632. doi:10.2174/138161211796196954 · PMID 21548867
2. Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. identifier not held by the Institute Cited by the Institute as an indicative analytical survey; sample frame was not random. The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.
3. Carvalho M, Dinis-Oliveira RJ. Analytical and forensic aspects of counterfeit peptide hormones. Drug Testing and Analysis 2023;15(1):5–19. identifier not held by the Institute The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.